GDS Wealth Management Has $326,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

GDS Wealth Management decreased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,973 shares of the company’s stock after selling 736 shares during the quarter. GDS Wealth Management’s holdings in AstraZeneca were worth $326,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in AZN. Jennison Associates LLC boosted its stake in shares of AstraZeneca by 3.1% during the 4th quarter. Jennison Associates LLC now owns 15,430,963 shares of the company’s stock worth $1,011,037,000 after acquiring an additional 466,416 shares during the period. FSM Wealth Advisors LLC boosted its stake in shares of AstraZeneca by 3.3% during the 4th quarter. FSM Wealth Advisors LLC now owns 6,342 shares of the company’s stock worth $424,000 after acquiring an additional 204 shares during the period. HHM Wealth Advisors LLC boosted its stake in shares of AstraZeneca by 38.8% during the 4th quarter. HHM Wealth Advisors LLC now owns 1,163 shares of the company’s stock worth $76,000 after acquiring an additional 325 shares during the period. Stock Yards Bank & Trust Co. boosted its stake in shares of AstraZeneca by 17.8% during the 4th quarter. Stock Yards Bank & Trust Co. now owns 8,116 shares of the company’s stock worth $532,000 after acquiring an additional 1,224 shares during the period. Finally, Valley National Advisers Inc. boosted its stake in shares of AstraZeneca by 2.2% during the 4th quarter. Valley National Advisers Inc. now owns 23,470 shares of the company’s stock worth $1,537,000 after acquiring an additional 508 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 1.3 %

Shares of AstraZeneca stock opened at $69.86 on Tuesday. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The stock’s 50-day moving average is $67.08 and its 200 day moving average is $73.85. The firm has a market cap of $216.64 billion, a price-to-earnings ratio of 33.43, a PEG ratio of 1.18 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.87 earnings per share. Equities research analysts anticipate that AstraZeneca PLC will post 4.13 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on AZN shares. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.